HBP:CC - Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
(TheNewswire)
March 18, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, announces thefiling of the Company’s unaudited interim financial statements as ofand for the three and six month periods ended January 31, 2025 (the “FinancialStatements” ), the management’s discussionand analysis ( “MD&A” ), and the certifications of theChief Executive Officer and Chief Financial Officer (respectively, “CEO” and “CFO” ) relating to the FinancialStatements (collectively, the “Interim Filings” ). The Interim Filingsare available on the Company’s profile at www.sedarplus.ca .
About Helix BioPharma
Helix BioPharma Corp. is an oncology company shaping anear future where today’s hard-to-treat cancers are made vincible bynovel therapies that rise to the challenge. The Company innovates fromstrength to tackle cancer’s biggest, most urgent challenges with adiverse pipeline of drug candidates with great potential and a headstart, honed into first- and best-in-class oncology medicines. Itspipeline is spearheaded by a clinical-stage proprietary technologyplatform of bio-conjugates that score with precision against prevalentCEACAM6-expressing solid tumors. Its lead candidate, Tumour DefenceBreaker TM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC)that neutralizes the microenvironment of common, hard-to-treat solidtumors, taking the brakes off anti-cancer immunity and delivering agame-changing assist to today’s front-running anti-cancer therapies.L-DOS47 has completed Phase Ib studies in non-small cell lung cancer(NSCLC), with novel strategically designed bi-specific ADCs targetingCEACAM6 in discovery.
Helix is listed on the TSX under the symbol “HBP”,on OTC PINK under the symbol “HBPCD” and on FWB under the symbol“HBP0”. For more information, please visit: https://www.helixbiopharma.com/
For more information, pleasecontact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: 604-428-7050
Jacek Antas, Director
Forward-Looking Statements and Risksand Uncertainties
This news release contains certainstatements regarding Helix BioPharma Corp. that constituteforward-looking statements and information (collectively, “forwardlooking statements”) as defined by Canadian securities laws.Forward-looking statements are statements and information that are nothistorical facts but instead include statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to its CEACAM6 platform,L-DOS47 and new asset transactions that Helix intends to close.Forward-looking statements can further be identified by the use offorward-looking terminology such as “will”, “plans”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.
Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward- looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements areintended to provide information about management’s current plans andexpectations regarding future operations and may not be appropriatefor other purposes. Certain material factors, estimates or assumptionshave been applied in making forward-looking statements in this newsrelease. The Company’s actual results could differ materially fromthose anticipated in the forward-looking statements contained in thisnews release as a result of numerous known and unknown risks anduncertainties, including the risk factors discussed in the Company’scontinuous disclosure record filed under the Company’s profile onSEDAR+ at www.sedarplus.ca from time to time. Forward-looking statements and information arebased on the beliefs, assumptions, opinions and expectations ofHelix’s management on the date of this new release, and the Companydoes not assume any obligation to update any forward-looking statementor information should those beliefs, assumptions, opinions orexpectations, or other circumstances change, except asrequired.
_________________
Copyright (c) 2025 TheNewswire - All rights reserved.